Almost a yr in the past we concluded that AI Drug Discovery Shares Proceed to Disappoint. One of the best examples are two names we cowl carefully that seemingly pivoted from “thrilling AI-enabled drug discovery platforms” to “dangerous in-house drug builders.” Since then, the 2 have run equally in reverse instructions with one up +36% and one down 36% […]
Source link
